Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Atezolizumab plus chemo gives slight PFS edge in mUC
Key clinical point: Atezolizumab combined with platinum-based chemotherapy slightly but significantly improved progression-free survival over chemotherapy plus placebo.
Major finding: Median PFS was 8.2 months with atezolizumab/chemotherapy vs. 6.3 months with chemotherapy alone.
Study details: Phase 3 randomized trial of 1,213 patients with previously untreated metastatic urothelial carcinoma.
Disclosures: The IMvigor130 study is sponsored by F. Hoffman-La Roche. Dr. Grande disclosed honoraria and research grants from Roche and others. Dr. Powles disclosed research funding, honoraria, and travel costs from Roche and others.
Citation:
Grande E et al. ESMO 2019. Abstract LBA14_PR.